Lyell Immunopharma annual current ratio
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Current Ratio Growth & History (LYEL)
Lyell Immunopharma's current ratio was 5.28 for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 5.28 | −1.78 | −25.17% |
| 2024 | 2024-12-31 | 7.06 | −9.01 | −56.08% |
| 2023 | 2023-12-31 | 16.07 | −1.52 | −8.64% |
| 2022 | 2022-12-31 | 17.59 | 4.19 | +31.26% |
| 2021 | 2021-12-31 | 13.40 | 0.87 | +6.94% |
| 2020 | 2020-12-31 | 12.53 | — | — |
Lyell Immunopharma quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.36 | −2.29 | −29.96% |
| Q1 2026 | 2026-03-31 | 7.23 | −0.25 | −3.39% |
| Q4 2025 | 2025-12-31 | 5.28 | −1.78 | −25.17% |
| Q3 2025 | 2025-09-30 | 10.30 | −3.13 | −23.34% |
| Q2 2025 | 2025-06-30 | 7.65 | −8.54 | −52.75% |
| Q1 2025 | 2025-03-31 | 7.49 | −9.02 | −54.64% |
| Q4 2024 | 2024-12-31 | 7.06 | −9.01 | −56.08% |
| Q3 2024 | 2024-09-30 | 13.43 | −3.31 | −19.76% |
| Q2 2024 | 2024-06-30 | 16.19 | −1.45 | −8.20% |
| Q1 2024 | 2024-03-31 | 16.51 | −3.76 | −18.57% |
| Q4 2023 | 2023-12-31 | 16.07 | −1.52 | −8.64% |
| Q3 2023 | 2023-09-30 | 16.74 | 3.86 | +29.93% |
| Q2 2023 | 2023-06-30 | 17.63 | 4.37 | +33.00% |
| Q1 2023 | 2023-03-31 | 20.27 | 5.03 | +33.03% |
| Q4 2022 | 2022-12-31 | 17.59 | 4.19 | +31.26% |
| Q3 2022 | 2022-09-30 | 12.88 | 2.23 | +20.99% |
| Q2 2022 | 2022-06-30 | 13.26 | 0.14 | +1.11% |
| Q1 2022 | 2022-03-31 | 15.24 | — | — |
| Q4 2021 | 2021-12-31 | 13.40 | 0.87 | +6.94% |
| Q3 2021 | 2021-09-30 | 10.65 | — | — |
| Q2 2021 | 2021-06-30 | 13.11 | — | — |
| Q4 2020 | 2020-12-31 | 12.53 | — | — |
Lyell Immunopharma current ratio trends
Over the last five fiscal years, Lyell Immunopharma's current ratio decreased from 12.53 to 5.28, a change of −7.25. The latest reported quarter, Q2 2026, shows 5.36.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗